Differential analysis of glioblastoma multiforme proteome by a 2D-DIGE approach

BackgroundGenomics, transcriptomics and proteomics of glioblastoma multiforme (GBM) have recently emerged as possible tools to discover therapeutic targets and biomarkers for new therapies including immunotherapy. It is well known that macroscopically complete surgical excision, radiotherapy and chemotherapy have therapeutic limitations to improve survival in these patients. In this study, we used a differential proteomic-based technique (2D-Difference Gel Electrophoresis) coupled with matrix-assisted laser desorption/ionization-time of flight (MALDI-TOF) mass spectrometry to identify proteins that may serve as brain tumor antigens in new therapeutic assays. Five samples of patients presenting a GBM and five samples of microscopically normal brain tissues derived from brain epileptic surgery specimen were labeled and run in 2D-PAGE (Two-Dimensional Polyacrylamide Gel Electrophoresis) with an internal pool sample on each gel. Five gels were matched and compared with DIA (Difference In-gel Analysis) software. Differential spots were picked, in-gel digested and peptide mass fingerprints were obtained.ResultsFrom 51 protein-spots significantly up-regulated in GBM samples, mass spectrometry (MS) identified twenty-two proteins. The differential expression of a selected protein set was first validated by western-blotting, then tested on large cohorts of GBM specimens and non-tumor tissues, using immunohistochemistry and real-time RT-PCR.ConclusionsOur results confirmed the importance of previously described proteins in glioma pathology and their potential usefulness as biological markers but also revealed some new interesting targets for future therapies.

[1]  S. Kaul,et al.  Elevated levels of mortalin expression in human brain tumors. , 1997, Experimental cell research.

[2]  A. Sobel,et al.  The Ulip family phosphoproteins--common and specific properties. , 1998, European journal of biochemistry.

[3]  Y. Ihara,et al.  Collapsin Response Mediator Protein-2 Is Associated with Neurofibrillary Tangles in Alzheimer’s Disease* , 1998, The Journal of Biological Chemistry.

[4]  N. Cairns,et al.  Expression of the dihydropyrimidinase related protein 2 (DRP-2) in Down syndrome and Alzheimer's disease brain is downregulated at the mRNA and dysregulated at the protein level. , 1999, Journal of neural transmission. Supplementum.

[5]  Y. Ihara,et al.  Neurofibrillary tangle-associated collapsin response mediator protein-2 (CRMP-2) is highly phosphorylated on Thr-509, Ser-518, and Ser-522. , 2000, Biochemistry.

[6]  G. Lubec,et al.  Differences in protein level between neonatal and adult brain , 2000, Electrophoresis.

[7]  M. Scerrati,et al.  The level of manganese superoxide dismutase content is an independent prognostic factor for glioblastoma. Biological mechanisms and clinical implications , 2001, British Journal of Cancer.

[8]  G. Lubec,et al.  Aberrant expression of dihydropyrimidinase related proteins-2,-3 and -4 in fetal Down syndrome brain. , 2001, Journal of neural transmission. Supplementum.

[9]  Nan Hu,et al.  2D Differential In-gel Electrophoresis for the Identification of Esophageal Scans Cell Cancer-specific Protein Markers* , 2002, Molecular & Cellular Proteomics.

[10]  Rainer Cramer,et al.  Evaluation of Two-dimensional Differential Gel Electrophoresis for Proteomic Expression Analysis of a Model Breast Cancer Cell System* , 2002, Molecular & Cellular Proteomics.

[11]  M. Oshimura,et al.  Proteomics-based identification of differentially expressed genes in human gliomas: down-regulation of SIRT2 gene. , 2003, Biochemical and biophysical research communications.

[12]  P. Thibault,et al.  Identification of differentially expressed proteins in human glioblastoma cell lines and tumors , 2003, Glia.

[13]  Akira Yamaura,et al.  Molecular Classification and Survival Prediction in Human Gliomas Based on Proteome Analysis , 2004, Cancer Research.

[14]  Y. Suh,et al.  HUlip, a human homologue of unc-33-like phosphoprotein of Caenorhabditis elegans; Immunohistochemical localization in the developing human brain and patterns of expression in nervous system tumors , 2005, Journal of Neuro-Oncology.

[15]  Vani Santosh,et al.  Differential protein expression in human gliomas and molecular insights , 2005, Proteomics.

[16]  Bruno Zanotti,et al.  Proteomic studies on low- and high-grade human brain astrocytomas. , 2005, Journal of proteome research.

[17]  H. Mehdorn,et al.  Glioblastoma multiforme-report of 267 cases treated at a single institution. , 2005, Surgical neurology.

[18]  Kathryn S Lilley,et al.  Maximising sensitivity for detecting changes in protein expression: Experimental design using minimal CyDyes , 2005, Proteomics.

[19]  R. Reddel,et al.  Upregulation of mortalin/mthsp70/Grp75 contributes to human carcinogenesis , 2006, International journal of cancer.

[20]  F. Tortella,et al.  Novel Differential Neuroproteomics Analysis of Traumatic Brain Injury in Rats* , 2006, Molecular & Cellular Proteomics.

[21]  S. Salani,et al.  Identification of a Primitive Brain–Derived Neural Stem Cell Population Based on Aldehyde Dehydrogenase Activity , 2006, Stem cells.

[22]  B. Eickholt,et al.  Distinct Priming Kinases Contribute to Differential Regulation of Collapsin Response Mediator Proteins by Glycogen Synthase Kinase-3 in Vivo* , 2006, Journal of Biological Chemistry.

[23]  J. Bansard,et al.  Expression of nine tumour antigens in a series of human glioblastoma multiforme: interest of EGFRvIII, IL-13Rα2, gp100 and TRP-2 for immunotherapy , 2006, Journal of Neuro-Oncology.

[24]  G. Kroemer,et al.  Heat Shock Proteins 27 and 70: Anti-Apoptotic Proteins with Tumorigenic Properties , 2006, Cell cycle.

[25]  H. Steinmetz,et al.  Serum GFAP is a diagnostic marker for glioblastoma multiforme. , 2007, Brain : a journal of neurology.

[26]  Ashraf A Khalil,et al.  Biomarker discovery: A proteomic approach for brain cancer profiling , 2007, Cancer science.

[27]  J. Mcculloch,et al.  Proteomic analysis of gliomas , 2007, British journal of neurosurgery.

[28]  Rieko Setsuie,et al.  The functions of UCH-L1 and its relation to neurodegenerative diseases , 2007, Neurochemistry International.

[29]  C. Pineau,et al.  Two-dimensional fluorescence difference gel electrophoresis analysis of spermatogenesis in the rat. , 2007, Journal of proteome research.

[30]  Daniel Birnbaum,et al.  ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. , 2007, Cell stem cell.

[31]  D. Busam,et al.  An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.

[32]  S. Sathornsumetee,et al.  Designer Therapies for Glioblastoma Multiforme , 2008, Annals of the New York Academy of Sciences.

[33]  Hans-Peter Lenhof,et al.  Proteomic study of human glioblastoma multiforme tissue employing complementary two-dimensional liquid chromatography- and mass spectrometry-based approaches. , 2009, Journal of proteome research.

[34]  H. Fine,et al.  SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. , 2009, Cell stem cell.

[35]  B. Cho,et al.  Multifarious proteomic signatures and regional heterogeneity in glioblastomas , 2009, Journal of Neuro-Oncology.

[36]  F. Bertucci,et al.  Aldehyde Dehydrogenase 1–Positive Cancer Stem Cells Mediate Metastasis and Poor Clinical Outcome in Inflammatory Breast Cancer , 2009, Clinical Cancer Research.

[37]  R. Yamanaka.  Dendritic-cell- and peptide-based vaccination strategies for glioma , 2009, Neurosurgical Review.

[38]  C. E. Fleming,et al.  Transthyretin: More than meets the eye , 2009, Progress in Neurobiology.

[39]  Chae-Yong Kim,et al.  Tissue Expression of Manganese Superoxide Dismutase Is a Candidate Prognostic Marker for Glioblastoma , 2009, Oncology.

[40]  J. Mcculloch,et al.  Glioma Pathophysiology: Insights Emerging from Proteomics , 2010, Brain pathology.

[41]  Fermín Sánchez de Medina,et al.  Reversible Ponceau staining as a loading control alternative to actin in Western blots. , 2010, Analytical biochemistry.

[42]  C. Iacobuzio-Donahue,et al.  Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. , 2010, Journal of the National Cancer Institute.

[43]  Lin Zhang,et al.  Distinct Expression Levels and Patterns of Stem Cell Marker, Aldehyde Dehydrogenase Isoform 1 (ALDH1), in Human Epithelial Cancers , 2010, PloS one.

[44]  D. Figarella-Branger,et al.  A2B5 Cells from Human Glioblastoma have Cancer Stem Cell Properties , 2010, Brain pathology.

[45]  S. Niclou,et al.  Glioma proteomics: status and perspectives. , 2010, Journal of proteomics.

[46]  J. Mcculloch,et al.  The Role of Mitochondria in Glioma Pathophysiology , 2010, Molecular Neurobiology.

[47]  R. Letón,et al.  Tumoral and tissue‐specific expression of the major human β‐tubulin isotypes , 2010, Cytoskeleton.

[48]  Kathleen Marchal,et al.  Alternative experimental design with an applied normalization scheme can improve statistical power in 2D-DIGE experiments. , 2010, Journal of proteome research.

[49]  M. Michalak,et al.  ERp57, a multifunctional endoplasmic reticulum resident oxidoreductase. , 2010, The international journal of biochemistry & cell biology.

[50]  P. Wen,et al.  Antiangiogenic strategies for treatment of malignant gliomas , 2009, Neurotherapeutics.